Woes for U.S. healthcare stocks have worsened this year driven partly by Trump administration policies, although some ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Meanwhile, mRNA vaccine maker Moderna is cutting around 500 jobs (10% of its workforce) as part of a commitment to save $1.5 ...

Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...

Merck has announced the acquisition of SpringWorks, which is expected to close this year, for an enterprise value of EUR 3 billion. While the deal appears expensive at an 18 times price/sales multiple ...

WASHINGTON (AP) — Health Secretary Robert F. Kennedy Jr. is vowing to “fix” the federal program for compensating Americans ...

Germany's Merck KGaA on Thursday raised its full-year operating earnings guidance, excluding the effect of harsh foreign ...

Merck & Co (NYSE: MRK) was the biggest spender in pharma M&A during July. The US pharma giant boldly splashed out around $10 ...

On August 4, Tom Lee, co-founder and managing partner of Fundstrat Capital, and chairman of BitMine, joined CNBC Television ...

Germany's Merck KGaA raised its full-year guidance for growth in underlying earnings, thanks to better prospects for its life-sciences and healthcare segments, but turned more cautious on sales.

Some high-profile healthcare names are at even cheaper valuations. For example, Merck is trading at a forward P/E of 8.7, ...

Summit Therapeutics Inc.'s valuation hinges on ivonescimab's potential, yet the data, competition, and regulatory issues ...